PUK15 - Cost-Effectiveness of Solifenacin for The Treatment of Overactive Bladder From A Us Private Payer and Medicare Advantage Perspective
| Autor: | Ng, DB, Wielage, R, Klein, TM, Klein, RW, Gooch, K |
|---|---|
| Zdroj: | In Value in Health November 2016 19(7):A519-A519 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect